Diplomat Pharmacy, Inc. (DPLO) Shares Bought by Vanguard Group Inc.

Vanguard Group Inc. boosted its stake in Diplomat Pharmacy, Inc. (NYSE:DPLO) by 5.4% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,077,145 shares of the company’s stock after buying an additional 210,334 shares during the quarter. Vanguard Group Inc. owned approximately 6.07% of Diplomat Pharmacy worth $60,342,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in the business. Louisiana State Employees Retirement System increased its stake in shares of Diplomat Pharmacy by 0.6% during the 2nd quarter. Louisiana State Employees Retirement System now owns 17,800 shares of the company’s stock worth $263,000 after purchasing an additional 100 shares during the last quarter. Capstone Asset Management Co. increased its stake in shares of Diplomat Pharmacy by 0.5% during the 2nd quarter. Capstone Asset Management Co. now owns 24,430 shares of the company’s stock worth $362,000 after purchasing an additional 120 shares during the last quarter. Arizona State Retirement System increased its stake in shares of Diplomat Pharmacy by 0.9% during the 2nd quarter. Arizona State Retirement System now owns 22,800 shares of the company’s stock worth $337,000 after purchasing an additional 200 shares during the last quarter. Bank of Montreal Can increased its stake in shares of Diplomat Pharmacy by 3.0% during the 2nd quarter. Bank of Montreal Can now owns 11,600 shares of the company’s stock worth $172,000 after purchasing an additional 340 shares during the last quarter. Finally, Texas Permanent School Fund increased its stake in shares of Diplomat Pharmacy by 1.5% during the 2nd quarter. Texas Permanent School Fund now owns 31,890 shares of the company’s stock worth $472,000 after purchasing an additional 470 shares during the last quarter. Institutional investors own 70.29% of the company’s stock.

Several research analysts have recently commented on the stock. Mizuho set a $16.00 price target on shares of Diplomat Pharmacy and gave the stock a “hold” rating in a research note on Tuesday, October 24th. BidaskClub lowered shares of Diplomat Pharmacy from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 17th. Zacks Investment Research upgraded shares of Diplomat Pharmacy from a “hold” rating to a “strong-buy” rating and set a $24.00 price target on the stock in a research note on Tuesday, October 10th. Needham & Company LLC restated a “buy” rating and set a $23.75 price target (up previously from $19.75) on shares of Diplomat Pharmacy in a research note on Wednesday, October 4th. Finally, Robert W. Baird upgraded shares of Diplomat Pharmacy to a “positive” rating and increased their price target for the stock from $20.00 to $24.00 in a research note on Monday, September 18th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. Diplomat Pharmacy has a consensus rating of “Hold” and an average price target of $19.36.

COPYRIGHT VIOLATION WARNING: This story was published by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright law. The original version of this story can be read at https://www.com-unik.info/2017/11/03/diplomat-pharmacy-inc-dplo-shares-bought-by-vanguard-group-inc.html.

Diplomat Pharmacy (NYSE:DPLO) last issued its earnings results on Monday, August 7th. The company reported $0.25 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.15 by $0.10. Diplomat Pharmacy had a net margin of 0.27% and a return on equity of 7.97%. The business had revenue of $1.13 billion for the quarter, compared to the consensus estimate of $1.14 billion. During the same period in the previous year, the company earned $0.23 earnings per share. The firm’s revenue for the quarter was up 3.5% on a year-over-year basis.

About Diplomat Pharmacy

Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.

Institutional Ownership by Quarter for Diplomat Pharmacy (NYSE:DPLO)

What are top analysts saying about Diplomat Pharmacy Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Diplomat Pharmacy Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit